CKD
MCID: CHR684
MIFTS: 69

Chronic Kidney Disease (CKD)

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases

Aliases & Classifications for Chronic Kidney Disease

MalaCards integrated aliases for Chronic Kidney Disease:

Name: Chronic Kidney Disease 12 29 6 42 3 15 37 62 17 32
Chronic Renal Disease 12 15
Chronic Renal Failure 74 6
Ckd 12 3
Chronic Renal Failure Syndrome 12
Renal Failure - Chronic 12
Kidney Failure, Chronic 44
Chronic Kidney Failure 12
Renal Failure Chronic 54
Crf 12

Classifications:



External Ids:

Disease Ontology 12 DOID:784
ICD9CM 34 585.6
MeSH 44 D007676
NCIt 50 C9438
SNOMED-CT 67 155856009
ICD10 32 N18 N18.9
UMLS 71 C0022661

Summaries for Chronic Kidney Disease

MedlinePlus : 42 You have two kidneys, each about the size of your fist. Their main job is to filter your blood. They remove wastes and extra water, which become urine. They also keep the body's chemicals balanced, help control blood pressure, and make hormones. Chronic kidney disease (CKD) means that your kidneys are damaged and can't filter blood as they should. This damage can cause wastes to build up in your body. It can also cause other problems that can harm your health. Diabetes and high blood pressure are the most common causes of CKD. The kidney damage occurs slowly over many years. Many people don't have any symptoms until their kidney disease is very advanced. Blood and urine tests are the only way to know if you have kidney disease. Treatments cannot cure kidney disease, but they may slow kidney disease. They include medicines to lower blood pressure, control blood sugar, and lower cholesterol. CKD may still get worse over time. Sometimes it can lead to kidney failure. If your kidneys fail, you will need dialysis or a kidney transplantation. You can take steps to keep your kidneys healthier longer: Choose foods with less salt (sodium) Control your blood pressure; your health care provider can tell you what your blood pressure should be Keep your blood sugar in the target range, if you have diabetes Limit the amount of alcohol you drink Choose foods that are healthy for your heart: fruits, vegetables, whole grains, and low-fat dairy foods Lose weight if you are overweight Be physically active Don't smoke NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Chronic Kidney Disease, also known as chronic renal disease, is related to kidney disease and renal osteodystrophy. An important gene associated with Chronic Kidney Disease is COL4A4 (Collagen Type IV Alpha 4 Chain), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Parathyroid hormone synthesis, secretion and action. The drugs Hydralazine and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A kidney failure that is characterized by the gradual loss of kidney function.

CDC : 3 CKD is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.

PubMed Health : 62 About chronic kidney disease: Our kidneys are vital organs that clean our blood and affect many different bodily functions. Various medical conditions can cause the kidneys to stop working properly for a short time – for example, if blood isn’t pumped around the body properly or if an enlarged prostate or kidney stones make urine build up in the kidneys. But if the kidneys still aren’t working at full capacity more than three months later or are permanently damaged, then the problem is considered to be chronic kidney disease. The most common causes in adults are diabetes and high blood pressure. Older people are especially prone to developing chronic kidney disease. It often goes unnoticed for a long time because poorly functioning kidneys don’t cause any problems at first. Treatment mostly aims to stop the kidney disease from getting worse, or at least delay the process. It is also important to treat complications such as anemia, acidosis or changes in bone metabolism. If the kidneys fail completely, dialysis or a kidney transplant can prolong the person’s life.

Wikipedia : 74 Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney... more...

Related Diseases for Chronic Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Renal Infectious Disease
Chronic Kidney Disease Ren-Related Kidney Disease

Diseases related to Chronic Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1544)
# Related Disease Score Top Affiliating Genes
1 kidney disease 33.5 UMOD PTH PKD2 PKD1 NPHS2 FGF23
2 renal osteodystrophy 33.3 PTH FGF23 CASR
3 secondary hyperparathyroidism 33.2 PTH FGF23 EPO CASR ALB
4 end stage renal disease 33.1 UMOD PTH PKD2 PKD1 NPHS2 GATA3
5 proteinuria, chronic benign 33.1 NPHS2 COL4A5 COL4A4 ALB ACE
6 hyperparathyroidism 32.9 PTH FGF23 EPO CASR ALB
7 deficiency anemia 32.9 PTH FGF23 EPO CRP ALB ACE
8 calciphylaxis 32.8 PTH FGF23 EPO CASR ALB
9 hyperphosphatemia 32.8 PTH FGF23 CRP CASR ALB
10 henoch-schoenlein purpura 32.7 CRP ALB ACE
11 diabetes mellitus 32.7 UMOD TUG1 PTH FGF23 EPO CRP
12 uremia 32.7 PTH EPO CRP CASR ALB ACE
13 hypokalemia 32.6 CASR ALB ACE
14 vascular disease 32.6 PTH EPO CRP APOA1 ALB ACE
15 type 2 diabetes mellitus 32.6 FGF23 EPO CRP CASR APOA1 ALMS1
16 hyperuricemia 32.5 UMOD PTH CRP ALB
17 rickets 32.5 PTH FGF23 CASR ALB
18 congestive heart failure 32.5 EPO CRP ALB ACE
19 hypoparathyroidism 32.5 PTH GATA3 FGF23 CASR
20 peripheral vascular disease 32.4 EPO CRP APOA1 ALB ACE
21 pierson syndrome 32.4 NPHS2 COL4A5 COL4A4
22 bone disease 32.4 PTH FGF23 EPO CASR
23 arteries, anomalies of 32.4 CRP APOA1 ALB ACE
24 cystic kidney disease 32.4 UMOD PKD2 PKD1 MKS1 ALB ACE
25 hypoparathyroidism, sensorineural deafness, and renal disease 32.3 PTH NPHS2 GATA3 CASR
26 glomerulonephritis 32.3 NPHS2 COL4A5 COL4A4 CFH ALB ACE
27 nephrotic syndrome 32.2 NPHS2 APOA1 ALB ACE
28 sleep apnea 32.2 EPO CRP ALB ACE
29 coronary heart disease 1 32.2 CRP APOA1 ACE
30 myocardial infarction 32.2 EPO CRP CFH APOA1 ALB ACE
31 urinary tract infection 32.1 UMOD CRP ACE
32 osteoporosis 32.1 PTH FGF23 CRP CASR ALB ACE
33 bone resorption disease 32.0 PTH FGF23 CRP ALB
34 interstitial nephritis 32.0 UMOD CRP ALB ACE
35 nephrolithiasis 32.0 UMOD PTH FGF23 CASR
36 atherosclerosis susceptibility 32.0 TUG1 CRP APOA1 ALB ACE
37 peripheral artery disease 32.0 CRP APOA1 ACE
38 iron deficiency anemia 32.0 FGF23 EPO CRP
39 glomerular disease 32.0 ALB ACE
40 focal segmental glomerulosclerosis 32.0 NPHS2 COL4A5 COL4A4 ALB ACE
41 iga glomerulonephritis 32.0 NPHS2 CFH ALB ACE
42 hypertension, essential 32.0 UMOD PTH PKD2 PKD1 NPHS2 FGF23
43 intermediate coronary syndrome 31.9 CRP APOA1 ACE
44 acute cystitis 31.9 UMOD CRP ALB ACE
45 acute kidney failure 31.9 UMOD CFH ALB
46 polycystic kidney disease 31.9 UMOD PKD2 PKD1 MKS1 FGF23 EPO
47 body mass index quantitative trait locus 11 31.9 PTH GATA3 CRP CFH APOA1 ALB
48 pyelonephritis 31.9 UMOD CRP ALB ACE
49 urinary tract obstruction 31.9 UMOD CRP ALB ACE
50 autosomal dominant polycystic kidney disease 31.8 PKD2 PKD1 FGF23 ALB ACE

Graphical network of the top 20 diseases related to Chronic Kidney Disease:



Diseases related to Chronic Kidney Disease

Symptoms & Phenotypes for Chronic Kidney Disease

MGI Mouse Phenotypes related to Chronic Kidney Disease:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ACE ALB APOA1 CFH COL4A5 CRP
2 homeostasis/metabolism MP:0005376 10.35 ACE ALB ALMS1 APOA1 CASR CFH
3 growth/size/body region MP:0005378 10.31 ACE ALMS1 CASR CFH COL4A4 COL4A5
4 cellular MP:0005384 10.27 ALB ALMS1 APOA1 CASR EPO GATA3
5 hematopoietic system MP:0005397 10.25 ACE ALMS1 CASR CFH COL4A4 COL4A5
6 immune system MP:0005387 10.25 ACE ALB ALMS1 CASR CFH COL4A4
7 endocrine/exocrine gland MP:0005379 10.23 ACE ALB ALMS1 APOA1 CASR COL4A4
8 digestive/alimentary MP:0005381 10.08 ALB CASR COL4A4 FGF23 GATA3 MKS1
9 mortality/aging MP:0010768 10 ACE ALB CASR CFH COL4A4 COL4A5
10 liver/biliary system MP:0005370 9.91 ACE ALB ALMS1 APOA1 EPO MKS1
11 renal/urinary system MP:0005367 9.8 ACE ALB ALMS1 CASR CFH COL4A4
12 vision/eye MP:0005391 9.28 ACE ALMS1 CASR CFH COL4A4 COL4A5

Drugs & Therapeutics for Chronic Kidney Disease

PubMed Health treatment related to Chronic Kidney Disease: 62

The most suitable treatment for chronic kidney disease will depend on the cause and stage of the disease, as well as on the person’s life circumstances and preferences. If the kidneys are still working at a nearly normal level, treatment should aim to stop or slow down the progression of the disease. This is mainly done using medication to lower blood pressure levels and prevent cardiovascular disease . If you have diabetes , it's important to regulate your blood sugar levels. If complications such as anemia or bone metabolism disorders have already occurred, then more medications are used – such as medicines that contain iron or stimulate the production of blood , as well as medications called “phosphate binders.” If there is too much acid in your body, bicarbonates are used. In addition to the medication, the treatment will include a diet suited to the stage of the disease, drinking the right amounts of liquids and physical exercise . Dialysis or a kidney transplant are considered if the kidneys fail completely. In the vast majority of people with complete kidney failure , at least one of these options is possible. Some people make a conscious decision not to use either, accepting the fact that they could die soon afterwards. Palliative treatment may then be suitable for them – enabling a final phase of life that is as pleasant as possible.

Drugs for Chronic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 644)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydralazine Approved Phase 4 86-54-4 3637
2
Dalteparin Approved Phase 4 9005-49-6
3
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
4
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
5
Fosinopril Approved Phase 4 98048-97-6 55891
6
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
7
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
9
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
10
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
11
Digoxin Approved Phase 4 20830-75-5 30322 2724385
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Nadroparin Approved, Investigational Phase 4
14
Lactitol Approved, Investigational Phase 4 585-86-4 157355
15
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
16
Cinacalcet Approved Phase 4 226256-56-0 156419
17
Telavancin Approved Phase 4 372151-71-8
18
Iodine Approved, Investigational Phase 4 7553-56-2 807
19
Aminophylline Approved Phase 4 317-34-0 9433
20
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
21
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
22
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
23
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
24
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
25
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
26
Linagliptin Approved Phase 4 668270-12-0 10096344
27
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
28
Deflazacort Approved, Investigational Phase 4 14484-47-0
29
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
30 fluindione Approved, Investigational Phase 4 957-56-2
31
Insulin aspart Approved Phase 4 116094-23-6 16132418
32
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
33 Taurolidine Approved, Investigational Phase 4 19388-87-5
34
alemtuzumab Approved, Investigational Phase 4 216503-57-0
35
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
36
Liraglutide Approved Phase 4 204656-20-2 44147092
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
39
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
40
Amiloride Approved Phase 4 2016-88-8, 2609-46-3 16231
41
Ribavirin Approved Phase 4 36791-04-5 37542
42
Donepezil Approved Phase 4 120014-06-4 3152
43
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
44
Pantoprazole Approved Phase 4 102625-70-7 4679
45
Remifentanil Approved Phase 4 132875-61-7 60815
46
Desflurane Approved Phase 4 57041-67-5 42113
47
Captopril Approved Phase 4 62571-86-2 44093
48
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
49
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
50
Temocillin Approved, Investigational Phase 4 66148-78-5

Interventional clinical trials:

(show top 50) (show all 3076)
# Name Status NCT ID Phase Drugs
1 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
2 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
3 The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
4 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
5 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
6 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
7 Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
8 Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
9 Comparison of the Effects Between Keto-/Amino Acid Supplemented Low Protein Diet and Non-Supplemented Low Protein Diet in Patients With Stage Ⅴ Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
10 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
11 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients Unknown status NCT02355873 Phase 4
12 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
13 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
14 the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure Unknown status NCT03427944 Phase 4 Calcium Dobesilate group;Conventional Treatment group
15 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
16 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
17 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
18 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
19 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
20 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
21 Canadian Collaborative Group for the Prevention of Illness in Chronic Renal Disease. The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
22 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
23 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
24 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
25 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
26 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction-a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
27 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
28 Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies Unknown status NCT00277693 Phase 4 Spironolactone (drug)
29 Effect of Aliskiren on Muscle Sympathetic Nerve Activity (MSNA) in Hypertensive Patients With Chronic Kidney Disease Unknown status NCT00719316 Phase 4 Aliskiren
30 Phase 4 Study of Sarpogrelate That Prevent Contrast-induced Nephropathy Unknown status NCT01165567 Phase 4 sarpogrelate
31 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
32 Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD Unknown status NCT01820832 Phase 4 Calcitriol
33 Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
34 Intradialytic Exercise for Enhanced Dialysis Adequacy and Solute Removal in Chronic Kidney Disease Patients: A Randomised Controlled Trial. Unknown status NCT01481688 Phase 4
35 Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4) Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
36 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
37 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
38 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease:a Multicentre Open Study Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
39 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
40 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
41 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
42 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
43 Effects of Non-Glucose-Based Peritoneal Dialysis Solution "EXTRANEAL" on Changes in Leptin Levels and Sympathetic Activity Induced by Conventional Glucose-Based Dialysate "DIANEAL" in Patients on Peritoneal Dialysis Unknown status NCT01228279 Phase 4
44 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
45 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
46 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
47 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
48 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
49 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
50 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir

Search NIH Clinical Center for Chronic Kidney Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Kidney Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: kidney failure, chronic

Genetic Tests for Chronic Kidney Disease

Genetic tests related to Chronic Kidney Disease:

# Genetic test Affiliating Genes
1 Chronic Kidney Disease 29

Anatomical Context for Chronic Kidney Disease

MalaCards organs/tissues related to Chronic Kidney Disease:

40
Kidney, Bone, Endothelial, Bone Marrow, Liver, Thyroid, Neutrophil
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Kidney Disease:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Kidney Proximal Tubule Proximal Tubule Cells Affected by disease, potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Chronic Kidney Disease

Articles related to Chronic Kidney Disease:

(show top 50) (show all 53529)
# Title Authors PMID Year
1
Chronic kidney disease and cardiovascular mortality in patients with atrial fibrillation: European Society of Hypertension project - ESH A Fib. 61 42
33466138 2021
2
Acupoint injection treatment for non-dialysis dependent chronic kidney disease: A meta-analysis of randomized controlled trials. 61 42
33371063 2020
3
Loop Diuretics: Clinical Application Information for Nephrology Nurses and Practitioners. 42
33377756 2020
4
Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle? 54 61
20512104 2010
5
A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. 61 54
19929273 2010
6
Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. 61 54
20150846 2010
7
Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. 54 61
19955654 2010
8
A prospective study of brain natriuretic peptide levels in three subgroups: Stroke with hypertension, stroke without hypertension, and hypertension alone. 54 61
20436747 2010
9
Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. 54 61
20181004 2010
10
Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. 54 61
20025585 2009
11
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. 54 61
19347366 2009
12
Impact of pancreas transplantation on the quality of life of diabetic renal transplant recipients. 54 61
19857701 2009
13
[BNP and echocardiographic parameters in patients with chronic kidney disease and dialyzed patients]. 61 54
19947237 2009
14
Investigation of albumin properties in patients with chronic renal failure. 54 61
19707919 2009
15
Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. 54 61
19083024 2009
16
Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. 54 61
19535427 2009
17
Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. 54 61
19460838 2009
18
The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. 61 54
19473634 2009
19
Predictive value of C-reactive protein for major postoperative complications following off-pump coronary artery bypass surgery: prospective and observational trial. 54 61
19282606 2009
20
Acute and chronic metabolic acidosis interferes with aquaporin-2 translocation in the rat kidney collecting ducts. 54 61
19300448 2009
21
Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. 61 54
19096086 2009
22
Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. 61 54
19298916 2009
23
Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. 54 61
19138652 2009
24
Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. 61 54
18809976 2009
25
Leptin and lipid metabolism in chronic kidney failure. 61 54
19148833 2009
26
Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. 61 54
19597297 2009
27
New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. 54 61
19494617 2009
28
Insulin resistance in chronic uremia. 61 54
19121765 2009
29
Relationships of serum haptoglobin concentration with HbA1c and glycated albumin concentrations in Japanese type 2 diabetic patients. 61 54
19072031 2009
30
Impact of pancreatic allograft function on 1-year survival rates after simultaneous pancreatic-renal transplant. 54 61
19338493 2008
31
[Insulin resistance and chronic kidney disease]. 61 54
18514051 2008
32
Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipocalin levels in proteinuric patients with normal renal function. 61 54
18955901 2008
33
Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. 61 54
18971153 2008
34
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. 54 61
19090870 2008
35
Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option? 61 54
18855638 2008
36
[Plasma calcium in haemodialysis patients: total calcium or ionized calcium? Should we systematically provide a value of total corrected calcium on our protocols?]. 54 61
18957349 2008
37
Vitamin D binding protein and the need for vitamin D in hemodialysis patients. 54 61
18721734 2008
38
[The kidneys and hypertension]. 61 54
18770487 2008
39
Insulin therapy in renal disease. 54 61
18248491 2008
40
An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. 61 54
18496509 2008
41
The effect of chronic renal failure on drug metabolism and transport. 54 61
18680441 2008
42
Necrotizing fasciitis. Case report. 61 54
19093634 2008
43
PHEX, FGF23, DMP1 and beyond. 54 61
18660670 2008
44
Adipocytokines leptin and adiponectin, and measures of malnutrition-inflammation in chronic renal failure: is there a relationship? 54 61
18558297 2008
45
Vitamin D: an old prohormone with an emergent role in chronic kidney disease. 61 54
18587719 2008
46
[Peritoneal dialysis and insulin resistance in patients with chronic kidney disease due to nondiabetic nephropathy]. 61 54
18634374 2008
47
Urotensin II: a cardiovascular and renal update. 61 54
18277155 2008
48
Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). 54 61
18397721 2008
49
Coronary artery bypass graft surgery trends in New South Wales, Australia. 61 54
17662316 2008
50
Management of hyperglycemia in patients with diabetes mellitus and chronic renal failure. 54 61
18923754 2008

Variations for Chronic Kidney Disease

ClinVar genetic disease variations for Chronic Kidney Disease:

6 (show top 50) (show all 54)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GATA3 NM_001002295.2(GATA3):c.1051-1G>C SNV Pathogenic 430696 rs112417755 10:8115701-8115701 10:8073738-8073738
2 PKD1 NM_001009944.3(PKD1):c.2079dup (p.Pro694fs) Duplication Pathogenic 374141 rs1057518923 16:2165396-2165397 16:2115395-2115396
3 MKS1 NM_001165927.1(MKS1):c.1085_1087del (p.Ser362del) Deletion Pathogenic 217677 rs754279998 17:56285514-56285516 17:58208153-58208155
4 PKD2 NM_000297.4(PKD2):c.357_364delinsTAGGACG (p.Pro120fs) Indel Pathogenic 373955 rs1057518797 4:88929242-88929249 4:88008090-88008097
5 COL4A5 NM_033380.3(COL4A5):c.3614G>T (p.Gly1205Val) SNV Pathogenic 523547 rs1556446493 X:107911558-107911558 X:108668328-108668328
6 COL4A4 NM_000092.5(COL4A4):c.2906C>G SNV Pathogenic 449549 rs35138315 2:227917083-227917083 2:227052367-227052367
7 COL4A4 NM_000092.5(COL4A4):c.4603_4604del (p.Gln1535fs) Deletion Pathogenic 915852 2:227872939-227872940 2:227008223-227008224
8 SLC13A5 NM_177550.4(SLC13A5):c.231+2T>G SNV Likely pathogenic 183313 rs730882222 17:6610345-6610345 17:6707026-6707026
9 CFH NM_000186.4(CFH):c.2517C>A SNV Likely pathogenic 591005 rs1362306576 1:196706057-196706057 1:196736927-196736927
10 ALMS1 NM_015120.4(ALMS1):c.1735del (p.Arg579fs) Deletion Likely pathogenic 374506 rs777476179 2:73675386-73675386 2:73448259-73448259
11 NPHS2 NM_014625.3(NPHS2):c.413G>A (p.Arg138Gln) SNV Likely pathogenic 5360 rs74315342 1:179530462-179530462 1:179561327-179561327
12 NPHS2 NM_144696.6(AXDND1):c.3032-1891_3032-1890del Deletion Likely pathogenic 188823 rs749740335 1:179521755-179521756 1:179552620-179552621
13 COL4A4 NM_000092.5(COL4A4):c.2164+2T>G SNV Likely pathogenic 977307 2:227924850-227924850 2:227060134-227060134
14 PASK NM_015148.4(PASK):c.3533+1G>A SNV Uncertain significance 252572 rs140030739 2:242051654-242051654 2:241112239-241112239
15 PKD1 NM_001009944.3(PKD1):c.9898G>A (p.Gly3300Arg) SNV Uncertain significance 427112 rs777024498 16:2149887-2149887 16:2099886-2099886
16 CFHR1 NM_002113.3(CFHR1):c.911A>G SNV Uncertain significance 915865 1:196801047-196801047 1:196831917-196831917
17 GANAB NM_198334.3(GANAB):c.925C>T (p.Arg309Cys) SNV Uncertain significance 716421 rs1063445 11:62400108-62400108 11:62632636-62632636
18 ACTN4 NM_004924.6(ACTN4):c.928C>T (p.Arg310Trp) SNV Uncertain significance 915866 19:39207741-39207741 19:38717101-38717101
19 SOX17 NC_000008.11:g.54459704_54459709GCACCA[5] Microsatellite Uncertain significance 915867 8:55372258-55372259 8:54459698-54459699
20 FN1 NM_212482.3(FN1):c.4486C>T (p.Arg1496Trp) SNV Uncertain significance 779411 rs139078629 2:216251538-216251538 2:215386815-215386815
21 SLC9A3R1 NM_004252.5(SLC9A3R1):c.458G>A (p.Arg153Gln) SNV Uncertain significance 5271 rs41282065 17:72758167-72758167 17:74762028-74762028
22 APOA1-AS NM_000039.2(APOA1):c.388_390AAG[1] (p.Lys131del) Microsatellite Uncertain significance 636899 rs532489785 11:116706935-116706937 11:116836219-116836221
23 CFHR1 NM_002113.3(CFHR1):c.790+1G>A SNV Uncertain significance 915864 1:196799813-196799813 1:196830683-196830683
24 FN1 NM_212482.3(FN1):c.1070G>A (p.Gly357Glu) SNV Uncertain significance 791471 rs140926439 2:216289015-216289015 2:215424292-215424292
25 UMOD NM_003361.4(UMOD):c.1243C>T (p.Arg415Cys) SNV Uncertain significance 884577 16:20355434-20355434 16:20344112-20344112
26 PKD1 NM_001009944.3(PKD1):c.12460C>T (p.Arg4154Cys) SNV Uncertain significance 803159 rs115538130 16:2140180-2140180 16:2090179-2090179
27 COL4A1 NM_001845.6(COL4A1):c.161C>T (p.Pro54Leu) SNV Uncertain significance 196327 rs34004222 13:110866346-110866346 13:110213999-110213999
28 FREM1 NM_144966.5(FREM1):c.1640C>G (p.Ala547Gly) SNV Uncertain significance 366157 rs201056172 9:14842412-14842412 9:14842414-14842414
29 FN1 NM_212482.3(FN1):c.1775G>A (p.Arg592His) SNV Uncertain significance 790514 rs147831535 2:216284009-216284009 2:215419286-215419286
30 MFF-DT NM_000091.5(COL4A3):c.1886C>T SNV Uncertain significance 452348 rs139361545 2:228137792-228137792 2:227273076-227273076
31 EHHADH NM_001966.4(EHHADH):c.2108C>T (p.Ser703Phe) SNV Uncertain significance 774610 rs55752621 3:184910078-184910078 3:185192290-185192290
32 ZNF423 NM_001271620.2(ZNF423):c.2071C>T (p.Arg691Cys) SNV Uncertain significance 645949 rs757246232 16:49670812-49670812 16:49636901-49636901
33 DSTYK NM_015375.3(DSTYK):c.2776G>T (p.Asp926Tyr) SNV Uncertain significance 915849 1:205116700-205116700 1:205147572-205147572
34 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro) SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468
35 COL4A4 NM_000092.4(COL4A4):c.3055G>C (p.Glu1019Gln) SNV Uncertain significance 374041 rs1057518854 2:227915788-227915788 2:227051072-227051072
36 COL4A4 NM_000092.4(COL4A4):c.4217-15T>C SNV Uncertain significance 255039 rs200926310 2:227877028-227877028 2:227012312-227012312
37 WT1 NM_024426.6(WT1):c.576G>T (p.Gln192His) SNV Uncertain significance 915856 11:32456331-32456331 11:32434785-32434785
38 EHHADH NC_000003.12:g.185204731_185204732AG[1] Microsatellite Uncertain significance 915857 3:184922519-184922520 3:185204731-185204732
39 FN1 NM_212482.3(FN1):c.5954C>A (p.Pro1985His) SNV Uncertain significance 721814 rs148388245 2:216240375-216240375 2:215375652-215375652
40 CFHR5 NM_030787.3(CFHR5):c.622T>C (p.Cys208Arg) SNV Uncertain significance 279752 rs41299613 1:196964861-196964861 1:196995731-196995731
41 APOA1 NM_000039.3(APOA1):c.625G>A (p.Gly209Ser) SNV Uncertain significance 915860 11:116706703-116706703 11:116835987-116835987
42 CFHR1 NM_002113.3(CFHR1):c.727C>G SNV Uncertain significance 915861 1:196799749-196799749 1:196830619-196830619
43 FN1 NM_212482.4(FN1):c.7408G>C (p.Ala2470Pro) SNV Uncertain significance 915862 2:216226304-216226304 2:215361581-215361581
44 ARHGDIA NM_004309.6(ARHGDIA):c.*243G>A SNV Uncertain significance 915863 17:79826509-79826509 17:81868633-81868633
45 MFF-DT NM_000091.5(COL4A3):c.4700T>G (p.Ile1567Ser) SNV Uncertain significance 829912 rs371452712 2:228173979-228173979 2:227309263-227309263
46 CFHR5 NM_030787.4(CFHR5):c.486dup (p.Glu163fs) Duplication Uncertain significance 402534 rs565457964 1:196963258-196963259 1:196994128-196994129
47 TBX18 NM_001080508.3(TBX18):c.574G>T (p.Val192Leu) SNV Uncertain significance 915854 6:85469998-85469998 6:84760280-84760280
48 ANLN NM_018685.5(ANLN):c.575C>G (p.Ser192Trp) SNV Uncertain significance 915855 7:36445877-36445877 7:36406268-36406268
49 ETFB NM_001985.3(ETFB):c.292C>T (p.Arg98Cys) SNV Uncertain significance 203697 rs147353781 19:51856469-51856469 19:51353215-51353215
50 FN1 NM_212482.4(FN1):c.3130G>A (p.Val1044Met) SNV Uncertain significance 915850 2:216269235-216269235 2:215404512-215404512

Expression for Chronic Kidney Disease

Search GEO for disease gene expression data for Chronic Kidney Disease.

Pathways for Chronic Kidney Disease

Pathways related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11 NPHS2 COL4A5 COL4A4
2 10.95 PTH GATA3 FGF23 CASR
3 10.3 PTH FGF23

GO Terms for Chronic Kidney Disease

Cellular components related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.73 UMOD PKD2 PKD1 CASR
2 cilium GO:0005929 9.72 UMOD PKD2 PKD1 MKS1 ALMS1
3 extracellular region GO:0005576 9.7 UMOD PTH FGF23 EPO CRP COL4A5
4 endoplasmic reticulum lumen GO:0005788 9.65 FGF23 COL4A5 COL4A4 APOA1 ALB
5 ciliary membrane GO:0060170 9.54 UMOD PKD2 PKD1
6 cation channel complex GO:0034703 9.46 PKD2 PKD1
7 collagen type IV trimer GO:0005587 9.4 COL4A5 COL4A4
8 extracellular space GO:0005615 9.36 UMOD PTH FGF23 EPO CRP COL4A5
9 polycystin complex GO:0002133 9.16 PKD2 PKD1

Biological processes related to Chronic Kidney Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 PKD2 GATA3 FGF23 CRP CASR
2 cellular calcium ion homeostasis GO:0006874 9.67 UMOD PTH PKD2 CASR
3 response to estrogen GO:0043627 9.65 GATA3 EPO APOA1
4 cellular response to vitamin D GO:0071305 9.58 FGF23 CASR
5 protein heterotetramerization GO:0051290 9.57 PKD2 PKD1
6 placenta blood vessel development GO:0060674 9.56 PKD2 PKD1
7 detection of mechanical stimulus GO:0050982 9.55 PKD2 PKD1
8 kidney development GO:0001822 9.55 UMOD PKD2 PKD1 GATA3 ACE
9 positive regulation of signal transduction GO:0009967 9.54 PTH GATA3
10 cytoplasmic sequestering of transcription factor GO:0042994 9.51 PKD2 PKD1
11 branching morphogenesis of an epithelial tube GO:0048754 9.5 PKD1 MKS1 CASR
12 cellular phosphate ion homeostasis GO:0030643 9.49 UMOD FGF23
13 response to fibroblast growth factor GO:0071774 9.46 PTH CASR
14 mesonephric tubule development GO:0072164 9.43 PKD2 PKD1
15 mesonephric duct development GO:0072177 9.4 PKD2 PKD1
16 cell-cell signaling by wnt GO:0198738 9.26 PKD2 PKD1
17 phosphate ion homeostasis GO:0055062 9.13 UMOD PTH FGF23
18 metanephric ascending thin limb development GO:0072218 8.8 UMOD PKD2 PKD1

Sources for Chronic Kidney Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....